{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:58:13Z","timestamp":1720094293008},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T00:00:00Z","timestamp":1431388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10552-015-0598-0","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T04:49:44Z","timestamp":1431319784000},"page":"1055-1063","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Menopausal hormone therapy and mortality among endometrial cancer patients in the NIH-AARP Diet and Health Study"],"prefix":"10.1007","volume":"26","author":[{"given":"Ashley S.","family":"Felix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Arem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britton","family":"Trabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gretchen L.","family":"Gierach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yikyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"598_CR1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jsbmb.2013.05.001","volume":"142","author":"LA Brinton","year":"2014","unstructured":"Brinton LA, Felix AS (2014) Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 142:83\u201389","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"598_CR2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/0029-7844(94)00383-O","volume":"85","author":"D Grady","year":"1995","unstructured":"Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85(2):304\u2013313","journal-title":"Obstet Gynecol"},{"issue":"2","key":"598_CR3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ijc.27623","volume":"132","author":"B Trabert","year":"2013","unstructured":"Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, Brinton LA (2013) Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 132(2):417\u2013426","journal-title":"Int J Cancer"},{"issue":"9470","key":"598_CR4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(05)66455-0","volume":"365","author":"V Beral","year":"2005","unstructured":"Beral V, Bull D, Reeves G (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470):1543\u20131551","journal-title":"Lancet"},{"issue":"3","key":"598_CR5","first-page":"269","volume":"54","author":"SJ Robboy","year":"1979","unstructured":"Robboy SJ, Bradley R (1979) Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 54(3):269\u2013277","journal-title":"Obstet Gynecol"},{"issue":"4","key":"598_CR6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000299600","volume":"12","author":"DC Smith","year":"1981","unstructured":"Smith DC, Prentice RL, Bauermeister DE (1981) Endometrial carcinoma: histopathology, survival, and exogenous estrogens. Gynecol Obstet Invest 12(4):169\u2013179","journal-title":"Gynecol Obstet Invest"},{"issue":"3 Pt 1","key":"598_CR7","first-page":"289","volume":"70","author":"DB Petitti","year":"1987","unstructured":"Petitti DB, Perlman JA, Sidney S (1987) Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 70(3 Pt 1):289\u2013293","journal-title":"Obstet Gynecol"},{"issue":"1","key":"598_CR8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0090-8258(79)90008-8","volume":"8","author":"PB Underwood Jr","year":"1979","unstructured":"Underwood PB Jr, Miller MC, Kreutner A Jr, Joyner CA, Lutz MH (1979) Endometrial carcinoma: the effect of estrogens. Gynecol Oncol 8(1):60\u201373","journal-title":"Gynecol Oncol"},{"issue":"8201","key":"598_CR9","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0140-6736(80)92115-7","volume":"2","author":"J Collins","year":"1980","unstructured":"Collins J, Donner A, Allen LH, Adams O (1980) Oestrogen use and survival in endometrial cancer. Lancet 2(8201):961\u2013964","journal-title":"Lancet"},{"issue":"5","key":"598_CR10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0002-9378(82)90549-X","volume":"143","author":"J Chu","year":"1982","unstructured":"Chu J, Schweid AI, Weiss NS (1982) Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol 143(5):569\u2013573","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"598_CR11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/oxfordjournals.aje.a114722","volume":"126","author":"JA Schwartzbaum","year":"1987","unstructured":"Schwartzbaum JA, Hulka BS, Fowler WC Jr, Kaufman DG, Hoberman D (1987) The influence of exogenous estrogen use on survival after diagnosis of endometrial cancer. Am J Epidemiol 126(5):851\u2013860","journal-title":"Am J Epidemiol"},{"issue":"3","key":"598_CR12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/bjc.1989.91","volume":"59","author":"A Paganini-Hill","year":"1989","unstructured":"Paganini-Hill A, Ross RK, Henderson BE (1989) Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 59(3):445\u2013447","journal-title":"Br J Cancer"},{"issue":"17","key":"598_CR13","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1016\/j.ejca.2009.05.012","volume":"45","author":"CC Orgeas","year":"2009","unstructured":"Orgeas CC, Hall P, Wedren S, Dickman PW, Czene K (2009) The influence of menopausal hormone therapy on tumour characteristics and survival in endometrial cancer patients. Eur J Cancer 45(17):3064\u20133073","journal-title":"Eur J Cancer"},{"issue":"12","key":"598_CR14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/aje\/154.12.1119","volume":"154","author":"A Schatzkin","year":"2001","unstructured":"Schatzkin A, Subar AF, Thompson FE, Harlan LC, Tangrea J, Hollenbeck AR et al (2001) Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study. Am J Epidemiol 154(12):1119\u20131125","journal-title":"Am J Epidemiol"},{"issue":"2","key":"598_CR15","first-page":"6","volume":"32","author":"D Michaud","year":"2005","unstructured":"Michaud D, Midthuner D, Hermansen S, Leitzmann MF, Harlan LC, Kipnis V, Schatzkin A (2005) Comparison of cancer registry case ascertainment with SEER estimates and Self-reporting in a subset of the NIH-AARP Diet and Health Study. J Regist Manag 32(2):6","journal-title":"J Regist Manag"},{"issue":"1","key":"598_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0b013e3181846c6d","volume":"28","author":"RJ Zaino","year":"2009","unstructured":"Zaino RJ (2009) FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28(1):1\u20139","journal-title":"Int J Gynecol Pathol"},{"issue":"7","key":"598_CR17","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/aje\/kwn404","volume":"169","author":"SW Hermansen","year":"2009","unstructured":"Hermansen SW, Leitzmann MF, Schatzkin A (2009) The impact on National Death Index ascertainment of limiting submissions to social security administration death master file matches in epidemiologic studies of mortality. Am J Epidemiol 169(7):901\u2013908","journal-title":"Am J Epidemiol"},{"issue":"7","key":"598_CR18","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1158\/1055-9965.EPI-05-0111","volume":"14","author":"JV Lacey Jr","year":"2005","unstructured":"Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C (2005) Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomark Prev 14(7):1724\u20131731","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"7","key":"598_CR19","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jama.288.7.872","volume":"288","author":"HD Nelson","year":"2002","unstructured":"Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288(7):872\u2013881","journal-title":"JAMA"},{"key":"598_CR20","doi-asserted-by":"crossref","unstructured":"Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. (2006) Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95 Suppl 1:S105\u201343","DOI":"10.1016\/S0020-7292(06)60031-3"},{"issue":"2","key":"598_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/gyno.1993.1107","volume":"49","author":"KR Mittal","year":"1993","unstructured":"Mittal KR, Barwick KW (1993) Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. Gynecol Oncol 49(2):197\u2013201","journal-title":"Gynecol Oncol"},{"issue":"2","key":"598_CR22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1006\/gyno.1993.1112","volume":"49","author":"HC Nyholm","year":"1993","unstructured":"Nyholm HC, Nielsen AL, Norup P (1993) Endometrial cancer in postmenopausal women with and without previous estrogen replacement treatment: comparison of clinical and histopathological characteristics. Gynecol Oncol 49(2):229\u2013235","journal-title":"Gynecol Oncol"},{"issue":"1","key":"598_CR23","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00001648-199801000-00020","volume":"9","author":"JA Shapiro","year":"1998","unstructured":"Shapiro JA, Weiss NS, Beresford SA, Voigt LF (1998) Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiology 9(1):99\u2013101","journal-title":"Epidemiology"},{"issue":"5","key":"598_CR24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0002-9378(96)70027-3","volume":"175","author":"JA Chapman","year":"1996","unstructured":"Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175(5):1195\u20131200","journal-title":"Am J Obstet Gynecol"},{"issue":"13","key":"598_CR25","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/jama.290.13.1739","volume":"290","author":"GL Anderson","year":"2003","unstructured":"Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M et al (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women\u2019s Health Initiative randomized trial. JAMA 290(13):1739\u20131748","journal-title":"JAMA"},{"issue":"10","key":"598_CR26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/oxfordjournals.aje.a008678","volume":"143","author":"KA Matthews","year":"1996","unstructured":"Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P (1996) Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 143(10):971\u2013978","journal-title":"Am J Epidemiol"},{"issue":"1","key":"598_CR27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jama.291.1.47","volume":"291","author":"AL Hersh","year":"2004","unstructured":"Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291(1):47\u201353","journal-title":"JAMA"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-015-0598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-015-0598-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-015-0598-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T18:17:34Z","timestamp":1566670654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-015-0598-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s10552-015-0598-0","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}